Thomas Laurell

Thomas Laurell: Professor in Medical and Chemical Microsensors at Lund University. Laurell has a background in engineering with a focus on biomedical technology, with a PhD from the technical faculty at Lund University. Laurell has 20 years experience in the development of lab-on-a-chip based bioanalytical and medical diagnostic technology. He was appointed distinguished professor at dept. Biomedical Engineering at Dongguk University, Seoul, Korea in 2009.

Laurell is a member of Royal Swedish Academy of Sciences,  of Royal Swedish Academy of Engineering Sciences  and Royal Physiographic Society. He has received several prestigious awards such as the The AkzoNobel Science Award in 2009 for his ground breaking interdisciplinary research, Wallmark Award by The Royal Swedish Academy of Sciences for his microsensorsystem innovations  in 2006, SKAPA Award in memory of Alfred Nobel – for the best innovation of the year in Sweden 1996 and 2003, and Erna Ebelings Price for outstanding research in microfluidics and biomedical engineering in 2006. He is founder of four start-up companies. Laurell is also the President of the Chemical and Biological Microsystems Society (www.cbmsociety.org).

Laurell has published over 130 papers in peer reviewed international journals with more than 3200 citations. He has filed 25 patent applications. His current research has a focus on nanobiotechnology based diagnostic technologies as well as nanoproteomics where prostate cancer is a major area of interest. He is head of the Div. Nanobiotechnology at his department as well as the Div. Clinical Protein Science at the Biomedical Centre. Laurell is currently managing a joint Vinnova, SSF and VR funded program, on new technologies in prostate cancer diagnostics, Biomedical Engineering for Better Health. He is also directing a Vinnova program, CellCARE (www.cellcare.lth.se), on new cell separation technologies in clinical medicine, where circulating tumor cells in prostate cancer is at focus. Laurell is also a PI within the Create Health consortium (www.createhealth.lth.se) with a core on new technologies in cancer diagnostics and therapeutics. He also holds separate funding from FORMAS, STINT, VR and Vinnova and is a PI in the Linnaeus consortium within Parkinson disease – Bagadilico.